

Florian H Heidel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6969567/publications.pdf>

Version: 2024-02-01

74
papers

2,645
citations

257101

24
h-index

197535

49
g-index

74
all docs

74
docs citations

74
times ranked

4624
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Combined Activity of the Redox-Modulating Compound Setanaxib (GKT137831) with Cytotoxic Agents in the Killing of Acute Myeloid Leukemia Cells. <i>Antioxidants</i> , 2022, 11, 513. | 2.2 | 4 |
| 2 | Interferon alpha for essential thrombocythemia during 34 high-risk pregnancies: outcome and safety. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1481-1491. | 1.2 | 8 |
| 3 | Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. <i>Cancers</i> , 2021, 13, 612. | 1.7 | 6 |
| 4 | The Role of MacroH2A Histone Variants in Cancer. <i>Cancers</i> , 2021, 13, 3003. | 1.7 | 21 |
| 5 | Significance of BK Polyomavirus in Long-Term Survivors after Adult Allogeneic Stem Cell Transplantation. <i>Biology</i> , 2021, 10, 553. | 1.3 | 1 |
| 6 | Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry. <i>Cancers</i> , 2021, 13, 4086. | 1.7 | 17 |
| 7 | A JAK of all trades: how global phosphoproteomics reveal the Achilles heel of MPNs. <i>Molecular and Cellular Oncology</i> , 2021, 8, 1871172. | 0.3 | 3 |
| 8 | Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance. <i>Cells</i> , 2021, 10, 2992. | 1.8 | 5 |
| 9 | Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. <i>Leukemia</i> , 2020, 34, 1075-1089. | 3.3 | 29 |
| 10 | Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252. | 2.0 | 106 |
| 11 | SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. <i>Leukemia</i> , 2020, 34, 1444-1449. | 3.3 | 7 |
| 12 | PLC β 1 suppression promotes the adaptation of KRAS-mutant lung adenocarcinomas to hypoxia. <i>Nature Cell Biology</i> , 2020, 22, 1382-1395. | 4.6 | 16 |
| 13 | Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. <i>Journal of Hematology and Oncology</i> , 2020, 13, 92. | 6.9 | 28 |
| 14 | Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments. <i>Cells</i> , 2020, 9, 2493. | 1.8 | 49 |
| 15 | Fibrosis and Immune Cell Infiltration Are Separate Events Regulated by Cell-Specific Receptor Notch3 Expression. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2589-2608. | 3.0 | 14 |
| 16 | Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo. <i>Leukemia</i> , 2020, 35, 2017-2029. | 3.3 | 27 |
| 17 | Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study. <i>Leukemia</i> , 2020, 34, 1949-1953. | 3.3 | 13 |
| 18 | Prevalence and dynamics of clonal hematopoiesis caused by leukemia-associated mutations in elderly individuals without hematologic disorders. <i>Leukemia</i> , 2020, 34, 2198-2205. | 3.3 | 26 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Hematopoietic stem and progenitor cell-restricted Cdx2 expression induces transformation to myelodysplasia and acute leukemia. <i>Nature Communications</i> , 2020, 11, 3021. | 5.8 | 15 |
| 20 | SIRT7: an influence factor in healthy aging and the development of age-dependent myeloid stem-cell disorders. <i>Leukemia</i> , 2020, 34, 2206-2216. | 3.3 | 27 |
| 21 | Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020, 38, 372-380. | 0.8 | 15 |
| 22 | Roles of JAK2 in Aging, Inflammation, Hematopoiesis and Malignant Transformation. <i>Cells</i> , 2019, 8, 854. | 1.8 | 119 |
| 23 | The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. <i>Leukemia</i> , 2019, 33, 2628-2639. | 3.3 | 27 |
| 24 | Memantine potentiates cytarabine-induced cell death of acute leukemia correlating with inhibition of Kv1.3 potassium channels, AKT and ERK1/2 signaling. <i>Cell Communication and Signaling</i> , 2019, 17, 5. | 2.7 | 20 |
| 25 | Plasma VCAM1 levels correlate with disease severity in Parkinson's disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 94. | 3.1 | 37 |
| 26 | Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. <i>Nature Communications</i> , 2019, 10, 2031. | 5.8 | 87 |
| 27 | Lack of CD45 in FLT3-ITD mice results in a myeloproliferative phenotype, cortical porosity, and ectopic bone formation. <i>Oncogene</i> , 2019, 38, 4773-4787. | 2.6 | 8 |
| 28 | Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 379-389. | 3.3 | 396 |
| 29 | Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, . | 5.8 | 166 |
| 30 | Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018. <i>Leukemia</i> , 2018, 32, 1055-1056. | 3.3 | 5 |
| 31 | The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function. <i>Leukemia</i> , 2018, 32, 1211-1221. | 3.3 | 15 |
| 32 | Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients. <i>Journal of Neuroinflammation</i> , 2018, 15, 99. | 3.1 | 20 |
| 33 | Efficacy and safety of ruxolitinib in intermediate- and high-risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290. | 0.8 | 29 |
| 34 | Epigenetic Erosion in Adult Stem Cells: Drivers and Passengers of Aging. <i>Cells</i> , 2018, 7, 237. | 1.8 | 15 |
| 35 | JAK2-V617F promotes venous thrombosis through β_1/β_2 integrin activation. <i>Journal of Clinical Investigation</i> , 2018, 128, 4359-4371. | 3.9 | 88 |
| 36 | Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions. <i>Leukemia</i> , 2018, 32, 2085-2087. | 3.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Diverging impact of cell fate determinants Scrib and Lgl1 on adhesion and migration of hematopoietic stem cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1933-1944. | 1.2 | 2 |
| 38 | Loss of DEP-1 (Ptpnj) promotes myeloproliferative disease in <i>FLT3-ITD</i> acute myeloid leukemia. <i>Haematologica</i> , 2018, 103, e505-e509. | 1.7 | 11 |
| 39 | Influence of Scribble polarity complex on hematopoiesis and leukemia - a matter of where, when and how. <i>Oncotarget</i> , 2018, 9, 34642-34643. | 0.8 | 1 |
| 40 | JAK2-V617F activates β 2-integrin-mediated adhesion of granulocytes to vascular cell adhesion molecule 1. <i>Leukemia</i> , 2017, 31, 1223-1226. | 3.3 | 20 |
| 41 | Gain of function in Jak2V617F-positive T-cells. <i>Leukemia</i> , 2017, 31, 1000-1003. | 3.3 | 11 |
| 42 | Hacking the stem cell niche. <i>Blood</i> , 2017, 129, 2951-2952. | 0.6 | 2 |
| 43 | RSK-mediated nuclear accumulation of the cold-shock Y-box protein-1 controls proliferation of T cells and T-ALL blasts. <i>Cell Death and Differentiation</i> , 2017, 24, 371-383. | 5.0 | 15 |
| 44 | Activated protein C protects from GvHD via PAR2/PAR3 signalling in regulatory T-cells. <i>Nature Communications</i> , 2017, 8, 311. | 5.8 | 35 |
| 45 | Macrophage's little helper: vitamin A directs alternatively activated monocyte-derived macrophages to tissue-resident macrophages. <i>Cellular and Molecular Immunology</i> , 2017, 14, 805-808. | 4.8 | 0 |
| 46 | Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis. <i>Leukemia</i> , 2017, 31, 889-895. | 3.3 | 16 |
| 47 | Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 807-820. | 1.2 | 8 |
| 48 | <i>Protein phosphatase 4 regulatory subunit 2 (PPP4R2)</i> is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair. <i>Oncotarget</i> , 2017, 8, 95038-95053. | 0.8 | 8 |
| 49 | Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of Ruxolitinib in vitro and in vivo. <i>Haematologica</i> , 2016, 101, e81-e85. | 1.7 | 11 |
| 50 | Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6. <i>Blood</i> , 2016, 127, 2890-2902. | 0.6 | 96 |
| 51 | Chronic myelogenous leukemia evolving after treatment of multiple myeloma. <i>Blood</i> , 2016, 128, 146-146. | 0.6 | 4 |
| 52 | Characteristics and treatment of polycythemia vera patients in clinical practice: a multicenter chart review on 1476 individuals in Germany. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 2041-2049. | 1.2 | 13 |
| 53 | Leukemic mastopathy. <i>International Journal of Hematology</i> , 2016, 103, 357-358. | 0.7 | 0 |
| 54 | Leukemogenic potency of the novel FLT3-N676K mutant. <i>Annals of Hematology</i> , 2016, 95, 783-791. | 0.8 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Impact of FLT3-ITD location on sensitivity to TKI-therapy in vitro and in vivo. <i>Leukemia</i> , 2016, 30, 1220-1225. | 3.3 | 33 |
| 56 | Specificity of JAK-kinase inhibition determines impact on human and murine T-cell function. <i>Leukemia</i> , 2016, 30, 991-995. | 3.3 | 21 |
| 57 | NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. <i>Leukemia</i> , 2016, 30, 473-483. | 3.3 | 54 |
| 58 | Kinomics Screening Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML. <i>Anticancer Research</i> , 2016, 36, 6249-6258. | 0.5 | 4 |
| 59 | Central Venous Catheterâ€“Related Bloodstream Infections in Obese Hematologic Patients. <i>Infection Control and Hospital Epidemiology</i> , 2015, 36, 995-996. | 1.0 | 5 |
| 60 | Prediction of central venous catheterâ€“related bloodstream infections (CRBSIs) in patients with haematologic malignancies using a modified Infection Probability Score (mIPS). <i>Annals of Hematology</i> , 2015, 94, 1451-1456. | 0.8 | 14 |
| 61 | Evolutionarily Conserved Signaling Pathways: Acting in the Shadows of Acute Myelogenous Leukemia's Genetic Diversity. <i>Clinical Cancer Research</i> , 2015, 21, 240-248. | 3.2 | 25 |
| 62 | Epo-induced erythroid maturation is dependent on Plc β 1 signaling. <i>Cell Death and Differentiation</i> , 2015, 22, 974-985. | 5.0 | 30 |
| 63 | Telomerase Inhibition Effectively Targets Mouse and Human AML Stem Cells and Delays Relapse following Chemotherapy. <i>Cell Stem Cell</i> , 2014, 15, 775-790. | 5.2 | 74 |
| 64 | Requirement for CDK6 in MLL-rearranged acute myeloid leukemia. <i>Blood</i> , 2014, 124, 13-23. | 0.6 | 139 |
| 65 | Germ and Hematology: Underlying Disease Influences Diversity of Germ Spectra and Antibiotic Therapy. <i>Infection Control and Hospital Epidemiology</i> , 2014, 35, 208-210. | 1.0 | 1 |
| 66 | Clinically relevant doses of FLT3-kinase inhibitors quizartinib and midostaurin do not impair T-cell reactivity and function. <i>Haematologica</i> , 2014, 99, e90-e93. | 1.7 | 14 |
| 67 | A rare cause of lower back pain. <i>Blood</i> , 2014, 124, 165-165. | 0.6 | 0 |
| 68 | Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature. <i>Journal of Hematology and Oncology</i> , 2013, 6, 39. | 6.9 | 10 |
| 69 | The cell fate determinant Lgl1 influences HSC fitness and prognosis in AML. <i>Journal of Experimental Medicine</i> , 2013, 210, 15-22. | 4.2 | 47 |
| 70 | Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- γ in a murine model of polycythemia vera. <i>Blood</i> , 2013, 121, 3692-3702. | 0.6 | 140 |
| 71 | Genetic and Pharmacologic Inhibition of β -Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML. <i>Cell Stem Cell</i> , 2012, 10, 412-424. | 5.2 | 209 |
| 72 | 3,4-Diarylmaleimidesâ€“a novel class of kinase inhibitorsâ€“effectively induce apoptosis in FLT3-ITD-dependent cells. <i>Annals of Hematology</i> , 2012, 91, 331-344. | 0.8 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Self-renewal related signaling in myeloid leukemia stem cells. International Journal of Hematology, 2011, 94, 109-117. | 0.7 | 41 |
| 74 | Focal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patients. Gastric Cancer, 2007, 10, 145-152. | 2.7 | 35 |